Antioxidant supplementation was associated with a decreased risk of first pulmonary exacerbation in 73 pancreatic insufficient Cystic Fibrosis (CF) subjects reported a recent trial published in American Journal of Respiratory and Critical Care Medicine. Further, the antioxidant treatment resulted in an increased systemic antioxidant concentration, reduced systemic inflammation after 4 weeks and was safe and well tolerated. The double-blind, controlled trial included 73 pancreatic insufficient cystic fibrosis (CF) subjects (10 years of age and older) with a predicted FEV1 between 40-100%.
The subjects were randomized to receive an antioxidant-enriched multivitamin or control multivitamin without antioxidant enrichment for 16 weeks. After 16 weeks, there was no significant difference in sputum myeloperoxidase concentration between the treated and control groups. The systemic antioxidant…
